Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3 h-benzimidazole-5-carboxamide

rosiglitazone has been researched along with 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3 h-benzimidazole-5-carboxamide in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hirosumi, J; Ita, M; Kawamura, I; Mabuchi, M; Manda, T; Minoura, H; Mutoh, S; Seki, J; Takakura, S; Takeshita, S; Yamamoto, T1
Aramori, I; Fujimura, T; Hosogai, N; Kimura, C; Konishi, S; Mutoh, S; Oe, T; Sakuma, H1
Aramori, I; Fujimura, T; Mutoh, S; Ohkubo-Suzuki, A; Sakuma, H1
Aramori, I; Fujimura, T; Kimura, C; Mutoh, S; Oe, T; Sakuma, H; Takata, Y1
Hirosumi, J; Kawamura, I; Kimura, C; Manda, T; Minoura, H; Mutoh, S; Seki, J; Takakura, S; Takeshita, S1

Other Studies

5 other study(ies) available for rosiglitazone and 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3 h-benzimidazole-5-carboxamide

ArticleYear
Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
    European journal of pharmacology, 2005, Sep-05, Volume: 519, Issue:1-2

    Topics: Administration, Oral; Animals; Benzimidazoles; Blood Glucose; Dose-Response Relationship, Drug; Glucose; Glucose Intolerance; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Metformin; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Time Factors

2005
FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators.
    Journal of pharmacological sciences, 2005, Volume: 99, Issue:4

    Topics: Benzimidazoles; CREB-Binding Protein; Genes, Reporter; Glutathione; Histone Acetyltransferases; Humans; Hybrid Cells; Hypoglycemic Agents; Ligands; Nuclear Receptor Coactivator 1; Pioglitazone; Plasmids; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transcriptional Activation

2005
Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma.
    Biological & pharmaceutical bulletin, 2006, Volume: 29, Issue:3

    Topics: Benzimidazoles; Glutathione; Hypoglycemic Agents; Kinetics; Ligands; Molecular Conformation; Peptide Hydrolases; Pioglitazone; Plasmids; PPAR gamma; Rosiglitazone; Spectrometry, Fluorescence; Thiazolidinediones

2006
A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 318, Issue:2

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3T3 Cells; Adipocytes; Animals; Benzimidazoles; Cell Differentiation; Chlorocebus aethiops; Collagen; Cyclic Nucleotide Phosphodiesterases, Type 3; Gels; Gene Expression; Hypoglycemic Agents; Insulin Resistance; Mice; Obesity; Pioglitazone; Plasmids; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Triglycerides

2006
Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
    Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:3

    Topics: Acyl-CoA Oxidase; Adipocytes, White; Adipose Tissue; Administration, Oral; Animals; Benzimidazoles; Biological Transport; Cell Count; Cell Size; Epididymis; Fatty Acid-Binding Proteins; Gene Expression; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Male; Muscle, Skeletal; Obesity; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones

2007